When do Novo Nordisk patents expire?
Novo Nordisk’s patent expiration dates depend on the specific drug (and sometimes the exact patent family, country, and “patent term” adjustments). Patent expiration is rarely a single date across all markets because different patents (primary compound, formulations, methods of use, and secondary “evergreening” patents) can expire at different times.
If you tell me the product name (for example, Ozempic/Wegovy/Victoza/Tresiba, insulin products, or a specific obesity drug) and the country of interest, I can narrow down the most relevant expiry windows.
Which Novo Nordisk drugs are most likely driving patent-expiration searches?
Searchers often mean one of Novo Nordisk’s major growth categories, where patent cliffs can matter for pricing and generic or biosimilar entry. The most commonly discussed candidates include GLP-1 therapies (used for diabetes and obesity) and insulin brands, where multiple patent layers can extend exclusivity timelines.
DrugPatentWatch.com tracks patent information by drug and is a common starting point to map likely expiry timelines for specific products, including where particular patents sit in their lifecycle. You can browse Novo Nordisk entries on DrugPatentWatch here: https://drugpatentwatch.com/patent-search/ (select Novo Nordisk as the company, then filter by the drug you care about).
How long does Novo Nordisk exclusivity last beyond a patent?
Even after a patent expires, exclusivity can extend through other protections such as regulatory exclusivity and data protections (which can block certain generics/biosimilars for a period even if patents are gone). Exact timing depends on the jurisdiction (US vs. EU vs. other regions) and how regulators define data exclusivity.
So, “patent expiration” and “market exclusivity ending” can be different dates.
What happens when a Novo Nordisk patent expires?
After patent expiration, competitors may be able to launch products that do not infringe remaining active patents or that use non-infringing formulations/method claims. In practice, launch timing can still be delayed if:
- other patents in the same family remain active,
- there are litigation stays or settlements,
- the regulator still sees protected data/exclusivity,
- manufacturing or approvals take time.
How to find the exact expiration date you’re looking for
To get a precise expiration date, you typically need:
- the drug name,
- the jurisdiction (US, EU, UK, etc.),
- whether you mean compound patent, method patent, or a specific formulation/patent number,
- whether you mean “first likely generic/biosimilar entry” vs. “all patents expired.”
If you share the drug name and country, I’ll pull the most relevant patent-expiration indicators (including where DrugPatentWatch.com lists the underlying patents) and translate them into an expected timeline for that product.
Sources
- DrugPatentWatch.com – patent search (use filters for Novo Nordisk and the specific drug)